Incretin Effect in People With Impaired Fasting Glucose (1651)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
University of Colorado, Denver
ClinicalTrials.gov Identifier:
NCT00795275
First received: November 20, 2008
Last updated: December 27, 2012
Last verified: November 2008
  Purpose

Regulation of endogenous glucose production (EGP) and insulin secretion are major actions of glucagon-like peptide-1 (GLP-1). Determining whether alterations in GLP-1 may contribute to abnormal EGP and insulin secretion in people with impaired fasting glucose (IFG) was the objective of the current study. The investigators hypothesized that defects in GLP-1 may explain the inappropriate basal EGP and diminished insulin secretion in IFG, and, furthermore, that by increasing circulating GLP-1 levels (using a new medicine called "sitagliptin") the investigators could reverse these defects.


Condition Intervention
Obesity
Drug: Januvia (sitagliptin phosphate)

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Exploring the Incretin Effect in People With IFG

Resource links provided by NLM:


Further study details as provided by University of Colorado, Denver:

Primary Outcome Measures:
  • Baseline and change in endogenous glucose production [ Time Frame: 28 days ] [ Designated as safety issue: No ]
  • Baseline and change in insulin secretion [ Time Frame: 28 days ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Insulin secretion in response to oral vs. IV glucose [ Time Frame: baseline ] [ Designated as safety issue: No ]
  • Baseline and change in hormones, substrates and insulin action [ Time Frame: 28 days ] [ Designated as safety issue: No ]

Enrollment: 23
Study Start Date: January 2008
Study Completion Date: November 2008
Primary Completion Date: August 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: IFG
people with impaired fasting glucose
Drug: Januvia (sitagliptin phosphate)
Januvia 100 mg po qd x 28 days for all subjects after baseline measures made
Experimental: NGT
people with normal glucose tolerance
Drug: Januvia (sitagliptin phosphate)
Januvia 100 mg po qd x 28 days for all subjects after baseline measures made

  Eligibility

Ages Eligible for Study:   45 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy, sedentary, non-smokers, men and women 45-70 years old Subjects were placed into 1 of the 2 groups based on two 2-hour 75g oral glucose tolerance tests (2h OGTT), separated by one week: a control group with normal glucose tolerance (NGT; n=14; fasting glucose <5.6 mmol/l and 2h OGTT <7.8 mmol/l), or IFG (n=10; fasting glucose 5.6-6.9 mmol/l, and 2h OGTT <7.8 mmol/l).

Exclusion Criteria:

  • Subjects were excluded for: thyroid stimulating hormone <50 or >500 mU/l, fasting triglycerides >10.3 mmol/l, creatinine >130 μmol/l, elevated liver function tests (>2X normal), hematocrit < 38%, or WBC<3.0 x 103. Use of medications for lipid and/or glucose lowering also excluded enrollees. Women may not have used hormone replacement therapy in the past 1 year. Smokers. BMI <25 or >40 kg/m2. Diabetes or impaired glucose tolerance.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00795275

Locations
United States, Colorado
University of Colorado Denver
Aurora, Colorado, United States, 80045
Sponsors and Collaborators
University of Colorado, Denver
Investigators
Principal Investigator: Leigh Perreault, MD University of Colorado, Denver
  More Information

No publications provided by University of Colorado, Denver

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: University of Colorado, Denver
ClinicalTrials.gov Identifier: NCT00795275     History of Changes
Other Study ID Numbers: 07-0749
Study First Received: November 20, 2008
Last Updated: December 27, 2012
Health Authority: United States: Institutional Review Board

Keywords provided by University of Colorado, Denver:
pre-diabetes
isotopes
insulin secretion
insulin action
GLP-1
simple obesity
impaired fasting glucose

Additional relevant MeSH terms:
Obesity
Overnutrition
Nutrition Disorders
Overweight
Body Weight
Signs and Symptoms
Incretins
Sitagliptin
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Pharmacologic Actions
Dipeptidyl-Peptidase IV Inhibitors
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Hypoglycemic Agents

ClinicalTrials.gov processed this record on July 26, 2014